 ll the company's business strategy, long -term interests and sustainability. Criteria SK A is determined, followed up and 
evaluated annually. Of total variable remuneration shall be a maximum of 50 percent based on financial criteria 
And a maximum of 50 percent on non -financial criteria. For the respective senior executives receive the moving 
The compensation constitutes a maximum of 50 percent of the fixed basic salary. 
The guidelines are available on page A 49-50 in the company's annual report for 2024. Some deviations from that in the guidelines 
determined the process of establishing compensation for senior executives has not been made under 
Previous financial year. Furthermore, no deviations from the guidelines have been made under the previous 
financial year. Variable remuneration paid to previous senior executives has not been subject to 
Recovery according to agreements during the previous financial year. 
Totally paid compensation to the CEO during the financial year 2024 (MSEK) 
The executive 
Name, Roll 1 - Fixed 21 June 30 2024 June 30, 2024 July 1, 2024 -
30 June 2025 3.50 612 689 - - - - 612 689 
 
1) Drawing options. 
2) Personnel options. 
3) performance options. 
4) warrants and employee stock options. 
5) The performance goals for the employee stock options were measured during the financial years 2021 –2023. 
 
 
Application of performance criteria 
CEO's performance during the reported financial year: Movable Cash Set 
The executive 
Name, Roll Description of Criteria attributable to 
the compensation component relative weighting of performance criteria a) measured performance and 
(b) actual allocation/compensation outcome 
(MSEK) 
Pål Ryfors, CEO's goal achievement for financial 
Criteria is assessed on the basis of set goals for 
commercial progress on global 
basis, quality goals, gross margins -
Improvements and product launch -
efforts. 
 
Target fulfillment in respect of non-
Financial criteria are assessed on the basis of 
set goals for progress regarding 
clinical studies, such as patient -
Recruitment, number of clinis Tering, number of clinical 
Publications available for b Olaget 
Technology, as well as the size of these. 100 %, of which 50 % for the financial targets 
And 50 % for the non -financial goals. a) 50 % 
b) 0.8

5 
 
D -6681064 -V2 CEO's performance during the reported financial year: share -based compensation 
The executive 
Name, Roll Description of Criteria attributable to 
the compensation component relative weighting of performance criteria a) measured performance and 
b) actual earnings /replacement outcome 
(MSEK) 
Pål Ryfors, CEO's goal achievement for financial 
Criteria R is assessed on the basis of set goals for 
commercial progress on global 
basis, quality goals, gross margins -
Improvements and product launch -
efforts. 
 
Target fulfillment in respect of non -
Financial criteria are assessed on the basis of 
set goals for progress regarding 
clinical studies, such as patient -
Recruitment, number of clinical 
Publications available for the Company's 
Technology, as well as the size of these. 100 %, of which 50 % for those %, of which 50 % for the financial targets 
And 50 % for the non -financial goals. a) 50 % 
b) - 
 
Annual changes 
The following table reports change in compensation to the CEO linked to the company's results and average 
Compensation to employees in the company and within the Episurf Group for the last five financial years 
("RAW"). 
Annual change, 
(MSEK) Information on Raw 
2024 RÅ 2024 VS RÅ 2023 RÅ 2023 Vs RÅ 2022 RÅ 2022 Vs RÅ 2021 RÅ 2021 Vs RÅ 2020 
Compensation to senior executives 
Pål Ryfors, CEO 
 4.9 
 +0.4 
(+8.0 %) -0.0 
(-0.2 %) +0.7 
(+17.5 %) +0.3 
(+8.1 %) 
The Group's results 
Operating profit -77.2 
 +19.5 
(+20.2 %) -19.7 
(-25.6 %) -7.6 
(-10.9 %) -6.1 
(-9.6 %) 
Average compensation for other employees (average employees during the financial year) 
Employed in the Company1) 
 0.6 
 -0.0 
(-1.1 %) -0.1 
(-10.5 %) +0.1 
(+9.8 %) +0.1 
(+9.4 %) 
Employees in 
Group1) 0.5 
 -0.3 
(-36.1 %) +0.1 
(+16.0 %) +0.0 
(+1.6 %) -0.1 
(-15.9 %) 
1) Oyrri